ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · IEX Real-Time Price · USD
20.10
-0.05 (-0.25%)
At close: May 17, 2024, 4:00 PM
20.62
+0.52 (2.59%)
After-hours: May 17, 2024, 6:51 PM EDT
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ArriVent BioPharma stock have an average target of 29.25, with a low estimate of 25 and a high estimate of 35. The average target predicts an increase of 45.52% from the current stock price of 20.10.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AVBP stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|
| Strong Buy | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +24.38% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +24.38% | Apr 30, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +49.25% | Feb 20, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +74.13% | Feb 20, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +34.33% | Feb 20, 2024 |
Financial Forecast
Revenue This Year
3.06M
Revenue Next Year
5.61M
from 3.06M
Increased by 83.33%
EPS This Year
-2.91
from -32.38
EPS Next Year
-2.42
from -2.91
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.3M | 11.6M | 17.1M | 147.0M | 127.2M |
| Avg | 3.1M | 5.6M | 8.3M | 102.6M | 123.5M |
| Low | n/a | n/a | n/a | 60.0M | 118.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 277.5% | 205.1% | 1,668.3% | 23.9% |
| Avg | - | 83.3% | 48.2% | 1,134.3% | 20.4% |
| Low | - | - | - | 621.5% | 15.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.53 | -1.61 | -1.76 |
| Avg | -2.91 | -2.42 | -2.03 |
| Low | -4.39 | -3.06 | -2.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.